FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

U.S. Drug Supply is Best Ever: CDER

The quality of the U.S. drug supply is the best it has ever been, according to CDER director of pharmaceutical quality Michael Kopcha, responding to a...

Federal Register

Guide on Oncology Drug Reproductive Toxicity Testing

Federal Register notice: FDA makes available a final guidance entitled Oncology Pharmaceuticals: Reproductive Toxicity Testing and Labeling Recommenda...

Medical Devices

Medical Device Safety Act Reintroduced

Reps Rosa DeLauro (D-CT), Jan Schakowsky (D-IL), and Brian Fitzpatrick (R-PA) reintroduced the Medical Device Safety Act, a bill to increase access to...

Human Drugs

Breakthrough Status for Sunovion Schizophrenia Drug

FDA grants Sunovion Pharmaceuticals and PsychoGenics a breakthrough therapy designation for SEP-363856, a novel agent for treating people with schizop...

Human Drugs

Abandon FDA Biologic Naming Plan: FTC

The Federal Trade Commission urges FDA to abandon its proposed naming convention for subsets of biologic products.

Federal Register

Draft Guide on Real World Data Submissions

Federal Register notice: FDA makes available a draft guidance entitled Submitting Documents Using Real-World Data and Real-World Evidence to FDA for D...

Federal Register

Pregnancy Safety Studies Draft Guide

Federal Register notice: FDA makes available a draft guidance entitled Postapproval Pregnancy Safety Studies that provides recommendations on how to d...

Federal Register

Draft Guide on Lactation Study Designs

Federal Register notice: FDA makes available a draft guidance entitled Clinical Lactation Studies: Considerations for Study Design.

Human Drugs

Maximal Usage Trial Monograph Guidance

FDA publishes a guidance with recommendations for designing and conducting maximal usage trials for topically applied active ingredients intended for ...

Human Drugs

ANDA vs. 505(b)(2) Determination Guidance

FDA publishes a guidance to help potential drug product applicants determine whether to submit an ANDA or a 505(b)(2) application.